Daniel L. Cruser

TL;DR: Although myocarditis/pericarditis (MP) has been identified as an adverse event following smallpox vaccine (SPX), the prospective incidence of this reaction and new onset cardiac symptoms, including possible subclinical injury, has not been prospectively defined as discussed by the authors.

TL;DR: In participants with Covid-19, most of whom were unvaccinated, the administration of convalescent plasma within 9 days after the onset of symptoms reduced the risk of disease progression leading to hospitalization.

TL;DR: Administration of high-titer CCP as post-exposure prophylaxis, while appearing safe, did not prevent SARS-CoV-2 infection.

TL;DR: In this article, the authors evaluated the efficacy of convalescent plasma therapy for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

TL;DR: The logistical considerations and workflow spanning procurement of qualified products, infrastructure, staffing, transfusion, and associated management of adverse events are described, to facilitate the efforts of others intent on establishing outpatient transfusion programs for CCP and other antibody‐based therapies.